Q3 2025 Transmedics Group Inc Earnings Call Transcript
Key Points
- TransMedics Group Inc (TMDX) reported a strong year-over-year revenue growth of 32.2% for Q3 2025, reaching approximately $144 million.
- The company experienced growth across all three organ segments, with liver revenues increasing by nearly 41%, heart by approximately 14%, and lung by about 5%.
- TransMedics Group Inc (TMDX) achieved a significant improvement in operating profit, reaching $23.3 million, which is more than 16% of total revenue, up from $3.9 million or approximately 4% of total revenue in Q3 2024.
- The company added approximately $65.6 million in cash to its balance sheet, ending Q3 with over $466.2 million in cash, indicating strong cash generation and healthy accounts receivable collections.
- Transplant logistics service revenue grew by 35% year-over-year, supported by the expansion of their aviation fleet and increased utilization, with 78% of NOP missions requiring air transport covered by their own aircraft.
- Despite the strong year-over-year growth, TransMedics Group Inc (TMDX) experienced a sequential decline in revenue, with US transplant revenue down 9% and OUS revenue down 13% compared to the previous quarter.
- The company's gross margin for Q3 2025, while improved year-over-year, declined sequentially by roughly 260 basis points due to lower activity levels and infrastructure investments.
- Operating expenses increased by 8% year-over-year, driven by a 7% increase in R&D expenses and ongoing expansion of IT infrastructure and strategic growth initiatives.
- The company anticipates some near-term pressure on margins as they expand internationally and continue investing ahead of growth, which may affect overall profitability.
- TransMedics Group Inc (TMDX) faces challenges in replicating their NOP model in Europe due to the fragmented nature of the market and varying clinical and regulatory requirements across different countries.
Good afternoon, and welcome to the TransMedics third-quarter 2025 earnings conference call. (Operator Instructions) As a reminder, this call is being recorded for replay purposes. (Operator Instructions)
I would now like to turn the call over to Ms. Laine Morgan from Gilmartin Group for a few introductory remarks. Thank you.
Thank you. Earlier today, TransMedics released financial results for the quarter ended September 30, 2025. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call, including during the question-and-answer portion of the call, that include forward-looking statements within the meaning of federal securities laws. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward-looking statements.
These forward-looking statements address various matters, including, among other things, future events, results and performance,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
